Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stage IV Melanoma
- Sponsor
- Power Life Sciences Inc.
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Rate of stage IV melanoma patients who remain in clinical trial to trial completion
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.
The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged ≥ 18 years old
- •Diagnosis of stage IV melanoma
- •Able to comprehend the investigational nature of the protocol and provide informed consent
Exclusion Criteria
- •Female patients who are currently pregnant or nursing
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Inability to perform regular electronic reporting
Outcomes
Primary Outcomes
Rate of stage IV melanoma patients who remain in clinical trial to trial completion
Time Frame: 12 months
Number of stage IV melanoma patients who decide to enroll in a clinical research
Time Frame: 3 months